Phathom Pharmaceuticals Reports Q3 2026 Revenue Growth and Sustained Operating Profitability
Phathom Pharmaceuticals (PHAT) reported third-quarter net revenues of $84.7 million, representing a 71% increase year-over-year. The biopharmaceutical company achieved its second consecutive quarter of operating profitability and positive cash flow, ending the period with $184.6 million in cash and cash equivalents. Management reaffirmed full-year 2026 revenue guidance in the range of $310 million to $325 million. To drive commercial momentum for its GERD treatment, VOQUEZNA, Phathom has implemented an 'Access First' strategy, including a $0 copay program through partner pharmacy BlinkRx for eligible commercially insured patients. Additionally, the company is actively defending its intellectual property in federal court following litigation from generic drug manufacturers challenging the FDA-extended exclusivity of VOQUEZNA, which is currently protected through May 2032.

Tickers: $PHAT
Topics: biotechnology cash flow earnings report operating profitability revenue growth